| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Reading Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Attention Deficit Disorder with Hyperactivity | |||||
| Disease | |||||
| Dyslexia | |||||
| Hyperkinesis | |||||
| 3 | More general conditions related to this trial | ||||
| Attention Deficit and Disruptive Behavior Disorders | |||||
| Communication Disorders | |||||
| Dyskinesias | |||||
| Language Disorders | |||||
| Learning Disorders | |||||
| Mental Disorders | |||||
| Mental Disorders Diagnosed in Childhood | |||||
| Nervous System Diseases | |||||
| Neurobehavioral Manifestations | |||||
| Neurologic Manifestations | |||||
| Pathologic Processes | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| Atomoxetine Hydrochloride | |||||
| placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Atomoxetine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| Eli Lilly and Company | |||||
|
